Lantheus Holdings to Acquire Evergreen Theragnostics for $250 Million Upfront

Lantheus Holdings has signed a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal with a $250 million upfront payment and up to $752.5 million in development and sales milestones. The acquisition is intended to expand Lantheus into a fully integrated radiopharmaceutical leader by adding Evergreen’s radiopharmaceutical CDMO manufacturing infrastructure and development capabilities, as well as the registrational-stage PET diagnostic agent OCTEVY.